Grace Therapeutics, Inc. Financial and Nonfinancial Liabilities, Fair Value Disclosure
Grace Therapeutics, Inc. (GRCE) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $2.96 million as of 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Notes › Fair Value, Net Asset (Liability)
us-gaap:LiabilitiesFairValueDisclosure · last filed 2024-08-09
- 2024-06-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $2.96M.
- 2024-03-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $4.36M.
- 2023-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $3.33M.
- 2023-09-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $3.46M.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2024-06-30 | $2.96M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $4.36M 10-Q · filed 2024-08-09 |
| 2023-12-31 | $3.33M 10-Q · filed 2024-02-12 |
| 2023-09-30 | $3.46M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |